Sharon Lim

Olympus invests $28m in Chinese cement(4)

Olympus Capital Holdings Asia has invested $28 million in a joint venture established with China-listed cement producer Sichuan Golden Summit.

Pantheon invests in Carlyle-backed Chinese flooring company(2)

Pantheon Ventures, a private equity fund of funds specialist, has invested $12.5 million in a Chinese wood flooring manufacturer backed by The Carlyle Group.

Permira buys from Olympus in first Japanese transaction(4)

Permira is acquiring Arysta LifeScience from rival Olympus Capital in a secondary deal, valuing the agrochemical business at $2.2 billion in Japan's largest buyout this year and Permira’s first in the country.

CVC Asia Pacific invests $225m in China-listed bottle maker(4)

CVC Asia Pacific has spent $225 million to acquire shares in a bottle maker in the largest private equity investment in tradable A-shares of a China-listed company.

CHAMP opens an office in Singapore(2)

CHAMP Private Equity, an Australia private equity firm, is expanding to Asia via a new office in Singapore. It is the first Australia-focused buyout group to do so.

3i invests $30m in designer jewellery brand(2)

3i has invested $30 million in John Hardy, a Hong Kong-based jewellery designer brand manufactured in Bali and sold in the US. The private equity investment will provide an exit for the founders of the family-run business.

Asia's battle for dry powder

Asian private equity is going through another record year of fund formation. Sharon Lim explains why, and asks for how much longer the boom can continue.

Carlyle hires investment banker to focus on southeast Asia(4)

The Carlyle Group has added to its Asian buyout team in Singapore, where the firm intends to build a team to focus on southeast Asia.

Olympus invests $28m in Chinese cement(3)

Olympus Capital Holdings Asia has invested $28 million in a joint venture established with China-listed cement producer Sichuan Golden Summit.

Permira buys from Olympus in first Japanese transaction(3)

Permira is acquiring Arysta LifeScience from rival Olympus Capital in a secondary deal, valuing the agrochemical business at $2.2 billion in Japan's largest buyout this year and Permira’s first in the country.